Feng Ye

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 8

Top Topics

Peritoneal Dialysis

Tyrosine Kinase

Epidermal Growth Factor Receptor

Top Venues

Nature communications

The EMBO journal

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Qiao Li, Jiaxuan Liu, Qingyuan Zhang, Quchang Ouyang, Yang Zhang, Qiang Liu, Tao Sun, Feng Ye, Baochun Zhang, Summer Xia, Bangyong Zhang, Binghe Xu
The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial. Nature communications 15 (1) (2024)
Qiao Li, Jiaxuan Liu, Qingyuan Zhang, Quchang Ouyang, Yang Zhang, Qiang Liu, Tao Sun, Feng Ye, Baochun Zhang, Summer Xia, Bangyong Zhang, Binghe Xu
The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial. Nature communications 15 (1) (2024)
Qiao Li, Jiaxuan Liu, Qingyuan Zhang, Quchang Ouyang, Yang Zhang, Qiang Liu, Tao Sun, Feng Ye, Baochun Zhang, Summer Xia, Bangyong Zhang, Binghe Xu
The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial. Nature communications 15 (1) (2024)
Qiao Li, Jiaxuan Liu, Qingyuan Zhang, Quchang Ouyang, Yang Zhang, Qiang Liu, Tao Sun, Feng Ye, Baochun Zhang, Summer Xia, Bangyong Zhang, Binghe Xu
The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial. Nature communications 15 (1) (2024)
Feng Ye, A-Bin You, Hu Yang, Guo-Sheng Hu, Chun-Ping Lai, Wen Liu, Feng Ye
A tumor suppressive-molecular axis EP300/circRERE/miR-6837-3p/MAVS activates type I interferon pathway and anti-tumor immunity to suppress colorectal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
A-Bin You, Hu Yang, Chun-Ping Lai, Wen Lei, Lu Yang, Jia-Lin Lin, Shun-Cui Liu, Nan Ding, Feng Ye
CMTR1 promotes colorectal cancer cell growth and immune evasion by transcriptionally regulating STAT3. Cell death & disease 14 (4) (2023)
Jia Yi, Lei Wang, Guo-Sheng Hu, Yue-Ying Zhang, Jiao Du, Jian-Cheng Ding, Xiang Ji, Hai-Feng Shen, Hai-Hua Huang, Feng Ye, Wen Liu
CircPVT1 promotes ER-positive breast tumorigenesis and drug resistance by targeting ESR1 and MAVS. The EMBO journal (2023)
Jiani Zheng, Jingxun Wu, Chunyue Wang, Shiwen Zhuang, Jianbo Chen, Feng Ye
Combination cyclin-dependent kinase 4/6 inhibitors and endocrine therapy versus endocrine monotherapy for hormonal receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: A systematic review and meta-analysis. PloS one 15 (6) (2020)